PRK Partners advised Affimed GmbH on the divestment of AbCheck
18. 一月 2024
PRK Partners is proud to have assisted its long-standing client, Affimed GmbH, a clinical-stage immuno-oncology company, in the successful divestment of AbCheck s.r.o., a Czech biotech company focusing on discovery and development of human therapeutic antibodies. Through the transaction, AbCheck became a wholly-owned subsidiary of Ampersand Biomedicines, a Flagship Pioneering company.
The transaction was jointly led by Monika Maskova and Milan Sivy who handled all aspects of the structuring, negotiation and completion of the transaction on behalf of the client and seamlessly coordinated the legal advice provided by counsel in the UK and US.
PRK Partners have been working with Affimed since 2008 when AbCheck was established as a spin-off of Affimed’s antibody technology discovery unit and have been providing legal advice on various issues ever since. We are excited to see a new chapter opening up for AbCheck.
